These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12414357

  • 1. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A.
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.
    J Clin Oncol; 2004 Jul 01; 22(13):2654-61. PubMed ID: 15159414
    [Abstract] [Full Text] [Related]

  • 3. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 4. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):627-36. PubMed ID: 16041313
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 6. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
    Van Oers MH, Hagenbeek A, Van Glabbeke M, Teodorovic I.
    Ann Hematol; 2002 Oct 01; 81(10):553-7. PubMed ID: 12424535
    [No Abstract] [Full Text] [Related]

  • 7. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA.
    Am J Hematol; 2002 Jul 01; 70(3):181-5. PubMed ID: 12111762
    [Abstract] [Full Text] [Related]

  • 8. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL.
    Oncologist; 2005 Feb 01; 10(2):150-9. PubMed ID: 15709217
    [Abstract] [Full Text] [Related]

  • 9. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May 01; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 10. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, Troch M, Puspok A, Zielinski CC, Chott A.
    Oncology; 2006 May 01; 70(6):411-7. PubMed ID: 17220639
    [Abstract] [Full Text] [Related]

  • 11. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.
    Ai Zheng; 2004 Dec 01; 23(12):1681-6. PubMed ID: 15601560
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [Abstract] [Full Text] [Related]

  • 13. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S.
    Clin Cancer Res; 2007 Oct 01; 13(19):5784-9. PubMed ID: 17908969
    [Abstract] [Full Text] [Related]

  • 14. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, Stelitano C, Angrilli F, Lazzaro A, Baldini L.
    Cancer; 2009 May 01; 115(9):1906-13. PubMed ID: 19248044
    [Abstract] [Full Text] [Related]

  • 15. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ.
    J Clin Oncol; 2004 Dec 01; 22(23):4711-6. PubMed ID: 15483015
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N, Khori M, Hayama M, Kajiwara K, Higashihara M, Tamaru J.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [Abstract] [Full Text] [Related]

  • 19. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H.
    Eur J Haematol; 2002 Jul 15; 69(1):21-6. PubMed ID: 12270058
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.